An observational study in Diabete Mellitus, Female Androgenetic Alopecia and Dermoscopy, sponsored by Al-Azhar University. Not yet recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Al-Azhar University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Diabetes Mellitus with a site in Egypt — 32 open to participants now, 41 under way, 2 of them phase 3. Diabetes Mellitus · Egypt.
Among the 146 studies in Diabetes Mellitus with a site in Egypt, this one is the 20th largest by planned enrollment of the 45 observational ones that give a count, is one of 12 that started in 2026, is one of 45 observational ones, reaches primary completion later than 35 of the 40 other live ones, and was the 143rd registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →32 of the 146 studies in Diabetes Mellitus with a site in Egypt are open now. Recruiting first, the newest first:
Badr University · Sites in Egypt
Ages 36–58
Alexandria University · Sites in Egypt
Ages 18+
Cairo University · Sites in Egypt
Ages 35–45 · Men only
Sara A Belal · Sites in Egypt
Ages 25+
Al-Azhar University · Sites in Egypt
Ages 18–75
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 20 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 12 · Phase 4 17
First in 2006; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is below the median of 246 across 1,936 observational studies indexed under Diabetes Mellitus.
Median enrollment 60 across the 101 interventional studies, 108 across the 45 observational. Of the 86 that completed or were terminated, 8 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 146 have an industry lead sponsor. The 10 most frequent:
Al-Azhar University is the lead sponsor of 535 studies on the registry; 173 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Al-Azhar University has 4 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
7 of the studies in Diabetes Mellitus with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496593Ain Shams UniversityTotal Intravenous and Balanced Anesthesia in Diabetic Patients Undergoing Video-Assisted Thoracoscopy | 2026-12-01 |
| NCT07306884Assiut UniversityNeurophysiological, Autonomic, and Sonographic Assessment of Diabetic Peripheral Neuropathy | 2027-01 |
| NCT07817277Al-Azhar UniversityHair Changes in Females With Type 2 Diabetes Clinical and Trichoscopic Examination | 2027-01-01 |
| NCT07928752Badr UniversityEffects of Adjunctive Melatonin Gel in Type II Diabetics With Stage III-IV Periodontitis | 2027-03 |
| NCT07204782Assiut UniversityCardiovascular Disease CVD Constitutes a Significant Health Challenge for Individuals With Type 2 Diabetes Mellitus T2DM, Affecting Approximately 32% of This Population and Contributing Significantly to Global Mortality.Visceral Adipose Tissue VAT Accumulation Has Been Recognize | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 146 studies in Diabetes Mellitus with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this thesis is to investigate the effect of diabetes mellitus on hair by assessing and comparing clinical and dermoscopic hair changes in diabetic patients versus age and sex-matched healthy controls.
The patients will be recruited from the dermatology and endocrinology outpatient clinics of Al-Zahraa University Hospital.
Inclusion criteria •
Cases:
Female patients aged 20-60 years Diagnosed with type 2 diabetes mellitus for at least 1 year HbA1c ≥ 6.5% o Consent to participate
Age-matched healthy females (no history of diabetes or insulin resistance) Normal fasting blood sugar (\<100 mg/dL) and HbA1c (\<5.7%) No known chronic illness Consent to participate Exclusion Criteria (for both groups)
All patients and control will undergo:
1. Full history taking 2. Clinical Assessment All participants will undergo generalized dermatological examination including the scalp and body hair. The following aspects will be documented: A. General Scalp Examination • Hair density: visual inspection (reduced, normal) • Scalp condition: erythema, scaling, atrophy, scarring • Presence of inflammation or follicular hyperkeratosis • Hair shaft fragility or breakage • Sebum level: dry, normal, oily
B. Hair Loss Type Classification Hair loss will be clinically categorized into one of the following types:
A. Sites Examined
Each site will be examined systematically, and the following features will be documented:
B. Dermoscopic Parameters Hair shaft diameter diversity (HSDD) >20% variation Yellow dots Peripilar signs (brown halos) Short vellus hairs Thin hairs \<30 μm Empty follicular openings Black dots Exclamation mark hairs Broken / dystrophic hairs
4. Blinding and Reproducibility
5. Photographic Documentation • High-resolution digital images of scalp regions 6. Laboratory investigations:
The following laboratory serum tests will be done:
The patients will be recruited from the dermatology and endocrinology outpatient clinics of Al-Zahraa University Hospital.
The patients will be recruited from the dermatology and endocrinology outpatient clinics of Al-Zahraa University Hospital.
Inclusion criteria • Cases: o Female patients aged 20-60 years o Diagnosed with type 2 diabetes mellitus for at least 1 year o HbA1c ≥ 6.5% o Consent to participate • Controls: o Age-matched healthy females (no history of diabetes or insulin resistance) o Normal fasting blood sugar (\<100 mg/dL) and HbA1c (\<5.7%) o No known chronic illness o Consent to participate Exclusion Criteria (for both groups) • Current pregnancy or lactation • Thyroid dysfunction • Polycystic ovary syndrome (PCOS) • Anemia (Hb \< 10 g/dL) • History of chemotherapy, radiotherapy, or recent acute illness • Scalp diseases (e.g., tinea capitis, scarring alopecia) • Recent use of drugs known to affect hair growth (e.g., isotretinoin, spironolactone).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cases:
≥ 6.5% o Consent to participate
Exclusion Criteria:
Current pregnancy or lactation
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evaluation of Hair Changes in Female Patients with Type 2 Diabetes Mellitus Versus Non-Diabetic Controls: A Clinical and Dermoscopic Cross-Sectional Study
Clinical Hair Assessment: 1. Hair loss pattern (diffuse, frontal, vertex, etc.) 2. Duration of hair loss (months/years) 3. Hair pull test results (positive/negative) Dermoscopic (Trichoscopic) Features: 1. Hair shaft diameter variability (%) 2. Presence of yellow dots, white dots, or peripilar signs 3. Follicular density (number/cm²) 4. Miniaturized hair count Metabolic and Laboratory Parameters: 1. BMI (kg/m²) 2. HbA1c (%) 3. Serum Ferritin (ng/mL) 4. Vitamin D3 (ng/mL) 5. TSH (µIU/mL) 6. Hemoglobin (g/dL) 7. ESR (mm/hr) Diabetes-Related Measures: 1. Duration of diabetes (years) 2. Presence of diabetic neuropathy (yes/no) Patient-Reported Outcomes Visual Analog Scale (VAS) for hair loss severity (ludwing scale-sinclair scale) Physician's Global Assessment of hair changes
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.